Abstract: The present disclosure discloses methods for culturing stem cells in three-dimensional methods. Said method is either a spheroid-based method or a microcarrier-based method. The process as described herein leads to the expansion of the stem cells to obtain an expanded population of the stem cells, and a stem cell derived-conditioned medium. The present disclosure also discloses an expanded population of the stem cells, and a stem cell derived-conditioned medium obtained from the process as described herein. Further, an exosome preparation obtained from the stem cell derived-conditioned medium is also disclosed herein. The present disclosure also discloses a composition comprising an expanded population of the stem cells, or a stem cell derived-conditioned medium, or an exosome preparation, or combinations thereof. Methods of treatment using the composition as described herein is also disclosed in the present disclosure.

Abstract: The present disclosure discloses a bioengineered formulation comprising: (a) a modified collagen peptide having a molecular weight in the range of 20-80 kDa, and with a degree of substitution in the range of 20-75%; and (b) a modified hyaluronic acid having a molecular weight in the range of 10-100 kDa, and with a degree of substitution in the range of 20-75%. The present disclosure also discloses the bioengineered formulation comprising stem cells, or exosomes, or combinations thereof. Further, the process for preparing the bioengineered formulation is also disclosed therein. Moreover, the formulation comprising: a) exosomes selected from the group consisting of corneal stromal stem cell derived-exosomes, primed mesenchymal stem cell derived-exosomes, and naive mesenchymal stem cell derived-exosomes; and (b) a clinically approved eye drop formulation is also provided.

Abstract: The present disclosure discloses a xeno-free bio-ink formulation amenable to be printed using a 3D printer. The bio-ink formulation exhibits optimum viscosity in the range of 1690-5300 cP. The present disclosure discloses a bio-printed corneal lenticule obtained from the bio-ink formulation. The bio-printed corneal lenticule as disclosed is of the optimum thickness in the range of 10-500 microns and exhibits transmittance in the range of 80-99%. The present disclosure also discloses a process for preparing the bio-ink formulation as well as for preparing the bio-printed corneal lenticule. Further, the present disclosure discloses a method of treating a corneal defect using the bio-printed corneal lenticule as an implant to treat the corneal defect. The bio-printed corneal lenticule can further be used as a model for in-vitro drug testing and diseases modelling.

Abstract: The present disclosure discloses embodiments of exosome compositions comprising primed mesenchymal stem cell-derived exosomes.

Abstract: The present disclosure discloses embodiments of a formulation for application to the cornea, the formulation comprising a hyaluronic acid, a gelatin, and exosomes. In certain variations, the exosomes may be naive mesenchymal stem cell-derived exosomes, primed mesenchymal stem cell derived-exosomes, or corneal stromal stem cell derived-exosomes. In certain variations, the primed mesenchymal stem cell-derived exosomes are exosomes derived from mesenchymal stem cells primed with a corneal stromal stem cell derived-conditioned medium.

Abstract: The present disclosure provides a process for obtaining an expanded primed mesenchymal stem cell population. In the process, the MSCs are cultured in the culture medium comprising a corneal stromal stem cell derived-conditioned medium to obtain the expanded population of the primed mesenchymal stem cell population along with the mesenchymal stem cell derived-conditioned medium. Also, provided is a method of culturing the MSCs in 3D culture using a spheroid-based method or a microcarrier-based method, in order to obtain the expanded primed mesenchymal stem cell population. Further, an exosome preparation obtained from the expanded primed mesenchymal stem cell derived-conditioned medium is also disclosed herein. The present disclosure also discloses a composition comprising an expanded population of the primed mesenchymal stem cells, or a primed mesenchymal stem cell derived-conditioned medium, or an exosome preparation, or combinations thereof.

Abstract: Disclosed herein is a synthetic polypeptide with “n” number of repeats of a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The synthetic polypeptide as disclosed herein is represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5. The synthetic polypeptide of the present disclosure is used to prepare synthetic elastomeric hydrogel. Also, disclosed are the methods of preparing the synthetic polypeptide and the elastomeric hydrogel along with their uses.

Abstract: Disclosed herein is a synthetic polypeptide with “n” number of repeats of a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The synthetic polypeptide as disclosed herein is represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5. The synthetic polypeptide of the present disclosure is used to prepare synthetic elastomeric hydrogel. Also, disclosed are the methods of preparing the synthetic polypeptide and the elastomeric hydrogel along with their uses.